3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 1/2
1
Status
Completed
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
2
Head & Neck
1
Gynecologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrent Platinum Resistant Ovarian Cancer
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Carcinoma
1
Adenoviridae Infections
1
Interventions
Paclitaxel
292
Gemcitabine
254
Carboplatin
254
Cisplatin
251
Radiotherapy
219
Cyclophosphamide
218
Irinotecan
184
pembrolizumab
181
Docetaxel
174
Bevacizumab
166
Capecitabine
148
Nivolumab
141
Fluorouracil
132
Dexamethasone
125
Bortezomib
123
Oxaliplatin
115
Cytarabine
113
Erlotinib Hydrochloride
112
Temozolomide
110
Sorafenib
110
Doxorubicin
106
Rituximab
105
Leucovorin
105
Etoposide
105
Filgrastim
99
Everolimus
97
Lenalidomide
95
Pemetrexed
90
Ipilimumab
90
fludarabine phosphate
84
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1
×
Completed
×
enadenotucirev
×
Clear all
NCT03916510
2025-02-06
CEDAR
University of Oxford
Phase 1
Completed
12 enrolled
13 charts
NCT02636036
2021-11-09
SPICE
Akamis Bio
Phase 1
Completed
51 enrolled
NCT02028117
2021-05-13
OCTAVE
Akamis Bio
Phase 1
Completed
38 enrolled